

February 15, 2016
Seikagaku Corporation
(Securities Code: 4548)

Seikagaku Announces New Drug Application Approval for the Ophthalmic Surgical Aid SHELLGAN[®] 0.5 Ophthalmic Viscoelastic Solution

Seikagaku Corporation (Tokyo) announced today the Japanese Ministry of Health, Labour and Welfare has approved the New Drug Application for SHELLGAN[®] 0.5 ophthalmic viscoelastic solution, a generic drug used as an ophthalmic surgical aid.

The active pharmaceutical ingredient of SHELLGAN[®] are purified sodium hyaluronate and chondroitin sulfate sodium. SHELLGAN[®] will be sold by Santen Pharmaceutical Co., Ltd. (Osaka), the sales partner for Seikagaku's ophthalmic surgical aid OPEGAN^{®*}. We are proceeding with preparations forward launching in June 2016 following listing in the National Health Insurance drug price list.

There will be no revision to the forecasts of consolidated results for fiscal 2015 as a result of this development.

*OPEGAN[®]: An ophthalmic surgical aid whose active pharmaceutical ingredient is purified sodium hyaluronate

#####